HC Wainwright Has Negative Outlook for BioNTech Q4 Earnings

BioNTech SE (NASDAQ:BNTX - Free Report) - Analysts at HC Wainwright decreased their Q4 2026 earnings per share estimates for BioNTech in a research report issued on Monday, June 16th. HC Wainwright analyst R. Burns now expects that the company will earn $0.88 per share for the quarter, down from their prior forecast of $0.90. HC Wainwright has a "Buy" rating and a $138.00 price objective on the stock. The consensus estimate for BioNTech's current full-year earnings is ($3.88) per share.

Other equities research analysts also recently issued research reports about the stock. JPMorgan Chase & Co. cut their price target on shares of BioNTech from $120.00 to $116.00 and set a "neutral" rating for the company in a report on Thursday, May 22nd. Truist Financial reissued a "buy" rating and set a $155.00 price target (up from $151.00) on shares of BioNTech in a report on Tuesday, June 3rd. Citigroup reissued a "buy" rating and set a $140.00 price target (down from $145.00) on shares of BioNTech in a report on Tuesday, May 6th. Leerink Partners set a $112.00 price target on shares of BioNTech in a report on Monday, June 2nd. Finally, BMO Capital Markets increased their target price on shares of BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a report on Tuesday, March 11th. Five equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $137.86.

BioNTech Stock Performance

NASDAQ BNTX opened at $106.33 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. BioNTech has a 1 year low of $76.53 and a 1 year high of $131.49. The company has a market capitalization of $25.56 billion, a PE ratio of -50.63 and a beta of 1.29. The company has a fifty day moving average of $101.37 and a two-hundred day moving average of $107.89.

Institutional Investors Weigh In On BioNTech

A number of institutional investors have recently modified their holdings of BNTX. Daiwa Securities Group Inc. boosted its stake in BioNTech by 7.1% during the 4th quarter. Daiwa Securities Group Inc. now owns 1,938 shares of the company's stock valued at $221,000 after purchasing an additional 128 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of BioNTech by 4.3% in the fourth quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company's stock valued at $419,000 after acquiring an additional 150 shares in the last quarter. Probity Advisors Inc. boosted its holdings in shares of BioNTech by 8.5% in the fourth quarter. Probity Advisors Inc. now owns 1,970 shares of the company's stock valued at $224,000 after acquiring an additional 154 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in shares of BioNTech by 9.1% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,494 shares of the company's stock valued at $227,000 after acquiring an additional 209 shares in the last quarter. Finally, Midwest Professional Planners LTD. boosted its holdings in shares of BioNTech by 5.8% in the fourth quarter. Midwest Professional Planners LTD. now owns 4,051 shares of the company's stock valued at $462,000 after acquiring an additional 222 shares in the last quarter. Institutional investors own 15.52% of the company's stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.